Publications and Media

Publications and Media

0
Peer Reviewed Publications
0
Abstracts
Bibliography 2023-2025

 

Peer-reviewed Publications:
  1. Shahzad M … Mushtaq MU. Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged 70 Years and Older: A Systematic Review and Meta-analysis. Transplantation and Cellular Therapy. 2025; 31(3):172 (PMID: 39755255)

  2. Shahzad M … Mushtaq MU. Outcomes with Allogeneic Hematopoietic Stem Cell Transplantation in Therapy Related Myeloid Neoplasms: A Systematic Review and Meta-Analysis. Clinical Lymphoma, Myeloma and Leukemia. 2025 (PMID: 39890517)

  3. Shahzad M … Mushtaq MU. Outcomes of hematopoietic stem cell transplantation in primary plasma cell leukemia: A systematic review and meta-analysis. Leukemia Research. 2024; 148: 107640 (PMID: 39724831)

  4. Zulfiqar F … Mushtaq MU. Outcomes with chimeric antigen receptor T-cell therapy in Rheumatological disorders: A systematic review. Transplant Immunology. 2024; 87: 102137 (PMID: 39442586)

  5. Shahzad M … Mushtaq MU. Efficacy of Ruxolitinib with corticosteroids in idiopathic pneumonia syndrome post-allogeneic hematopoietic stem cell transplantation: A single-center experience and systematic review. Transplant Immunology. 2024; 87: 102135 (PMID: 39368752)

  6. Rashid A, et al. Among other authors: Mushtaq MU. BCMA-Directed MRD Detection as a Predictor of Relapse after BCMA CAR T in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia. 2024 (PMID: 39516088)

  7. Barry P, et al. Among other authors: Mushtaq MU. Comparative Meta-Analysis of Triplet vs. Quadruplet Induction Regimens in Newly Diagnosed, Treatment Naïve, Multiple Myeloma. Cancers. 2024; 16(17): 2938 (PMID: 39272795)

  8. Shahzad M … Mushtaq MU. Comparison of Biosimilar Filgrastim and Originator Filgrastim for Peripheral Blood Stem Cell Mobilization for Allogeneic Hematopoietic Stem Cell Transplantation. Transfusion. 2024; 64(8): 1402-1406. (PMID: 38847196)

  9. Ammad Ud Din M … Mushtaq MU. The Impact of Early-to-Moderate Stage Chronic Kidney Disease on Hospitalization Outcomes in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant: A Nationwide Analysis Using the National Inpatient Sample Database (2002–2019). Transplantology 2024, 5(3), 140-147.

  10. Wesson W, et al. Among other authors: Mushtaq MU. Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma. Transplantation and Cellular Therapy. 2024 (PMID: 38871056)

  11. Atallah R, et al. Among other authors: Mushtaq MU. TACTUM: Trends in Access to Cellular Therapies in Multiple Myeloma, Perspectives of Treating Versus Referring Physicians. Transplantation and Cellular Therapy. 2024 (PMID: 38763416)

  12. Khaliq A, et al. Among other authors: Mushtaq MU. The Glass Wall: Gendered authorship disparities in CD 19 and BCMA CAR-T Clinical Trials for lymphoma and myeloma. Clinical Lymphoma, Myeloma and Leukemia. 2024 (PMID: 38910060)

  13. Bellman P … Mushtaq MU. Successful treatment with Fludarabine and Cyclophosphamide in a VEXAS syndrome patient with associated Myelodysplastic Syndrome: a case report and systemic review. Frontiers in Oncology. 2024; 14: 1383730. (PMID: 38665946)

  14. McGuirk M … Mushtaq MU. Predictors of cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: Insights from a real-world experience. Transplant Immunology. 2024; 84: 102039. (PMID: 38513813)

  15. Mushtaq MU, et al. Outcomes with HLA-matched unrelated donor versus haploidentical hematopoietic cell transplantation. Leukemia and Lymphoma. 2024; 65(4): 493-502. (PMID: 38164945)

  16. Shahzad M … Mushtaq MU. Outcomes with Allogeneic Hematopoietic Stem Cell Transplantation in TP53-mutated Myelodysplastic syndrome: A Systematic Review and Meta-Analysis. Critical Reviews in Oncology/Hematology. 2024: 104310. (PMID: 38423375)

  17. Shahzad M … Mushtaq MU. Use of Endpoints in Phase III Randomized Controlled Trials for Hematopoietic Stem Cell Transplantation Over the Last 15 Years: A Systematic Review. Hematology/Oncology and Stem Cell Therapy. 2024; 17(2): 1. (PMID: 38560970)

  18. Al-Ramahi J … Mushtaq MU. Lessons learned from COVID-19 pandemic: outcomes after SARS-CoV-2 infection in hematopoietic cell transplant and cell therapy recipients. Leukemia and Lymphoma. 2023; 64(12): 1981-1991. (PMID: 37574842)

  19. Al-Ramahi J … Mushtaq MU. Favorable outcomes following CD34-selected stem cell boost for poor graft function after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation. 2023; 59(1): 134-137. (PMID: 37833526)

  20. Ammad Ud Din M … Mushtaq MU. Poor hospitalization outcomes in patients undergoing allogeneic hematopoietic stem cell transplant with hospital acquired influenza infection. Transplant Infectious Disease. 2023; 25(3): e14066. (PMID: 37129229)

  21. Lutfi F, et al. Among other authors: Mushtaq MU. Imaging Biomarkers to Predict Outcomes in Patients With Large B-Cell Lymphoma With a Day 28 Partial Response by 18F-FDG PET/CT Imaging Following CAR-T Therapy. Clinical Lymphoma, Myeloma and Leukemia. 2023; 23(10): 757-763. (PMID: 37453865)

  22. Ahmed N, Wesson W, Mushtaq MU, et al. “Waitlist mortality” is high for myeloma patients with limited access to BCMA therapy. Frontiers in Oncology. 2023; 13: 1206715. (PMID: 37601685)

  23. Ahmed N, Wesson W, Mushtaq MU, et al. Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma. Transplantation and Cellular Therapy. 2023; 29(7): 449. (PMID: 37120134)

  24. Shahzad M … Mushtaq MU. Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Acute Myeloid Leukemia: A Systematic Review. Frontiers in Immunology. 2023; 14: 1152457. (PMID: 37168849)

  25. Shahzad M … Mushtaq MU. Outcomes of Tyrosine Kinase Inhibitors Maintenance Therapy with or without Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission: A Systematic Review and Meta-Analysis. Clinical Lymphoma, Myeloma and Leukemia. 2023; 23(3): 178-187. (PMID: 36682989)
Abstracts:
  1. Mushtaq MU, et al. Outcomes after Matched Sibling Donor Versus Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis. Transplantation and Cellular Therapy. 2025; 31(2): S267-268 (poster presented at the Transplantation and Cellular Therapy Meetings 2025, Honolulu, HI)

  2. Mushtaq MU, et al. Impact of Graft Cell Dose on Outcomes after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis. Transplantation and Cellular Therapy. 2025; 31(2): S301 (poster presented at the Transplantation and Cellular Therapy Meetings 2025, Honolulu, HI)

  3. Pfannenstiel K … Mushtaq MU. Pure Red Cell Aplasia Following ABO-Incompatible Hematopoietic Stem Cell Transplantation: A Single-Center Experience. Transplantation and Cellular Therapy. 2025; 31(2): S335-336 (poster presented at the Transplantation and Cellular Therapy Meetings 2025, Honolulu, HI)

  4. Ogle NR … Mushtaq MU. Efficacy of Daratumumab in Secondary Pure Red Cell Aplasia after ABO-Incompatible Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy. 2025; 31(2): S142 (poster presented at the Transplantation and Cellular Therapy Meetings 2025, Honolulu, HI)

  5. Snyder J, et al. Among other authors: Mushtaq MU. Use of BCMA Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Versus BCMA T-Cell Engagers in BCMA-Exposed Relapsed/Refractory Multiple Myeloma. Transplantation and Cellular Therapy. 2025; 31(2): S419 (poster presented at the Transplantation and Cellular Therapy Meetings 2025, Honolulu, HI)

  6. Shahzad M … Mushtaq MU. Impact of Minimal Residual Disease Status on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia. Transplantation and Cellular Therapy. 2025; 31(2): S126-127 (poster presented at the Transplantation and Cellular Therapy Meetings 2025, Honolulu, HI)

  7. Shahzad M … Mushtaq MU. Outcomes with Venetoclax and Hypomethylating Agents in Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis. Transplantation and Cellular Therapy. 2025; 31(2): S128-129 (poster presented at the Transplantation and Cellular Therapy Meetings 2025, Honolulu, HI)

  8. Shahzad M … Mushtaq MU. Outcomes of Melphalan Versus Busulfan with Fludarabine Reduced Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. Transplantation and Cellular Therapy. 2025; 31(2): S184-185 (poster presented at the Transplantation and Cellular Therapy Meetings 2025, Honolulu, HI)

  9. Shahzad M … Mushtaq MU. Outcomes after Bone Marrow Versus Peripheral Blood Matched Unrelated Donor Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide-Based GVHD Prophylaxis. Transplantation and Cellular Therapy. 2025; 31(2): S262-263 (poster presented at the Transplantation and Cellular Therapy Meetings 2025, Honolulu, HI)

  10. Shahzad M … Mushtaq MU. Incidence and Severity of Cytopenias Secondary to CD19-Targeted CAR-T Cell Therapy: A Systemic Review and Meta-Analysis. Transplantation and Cellular Therapy. 2025; 31(2): S171 (poster presented at the Transplantation and Cellular Therapy Meetings 2025, Honolulu, HI)

  11. Shahzad M … Mushtaq MU. Outcomes of Busulfan with Cyclophosphamide Versus Fludarabine for Myeloablative Conditioning Allogenic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis. Transplantation and Cellular Therapy. 2025; 31(2): S188 (poster presented at the Transplantation and Cellular Therapy Meetings 2025, Honolulu, HI)

  12. Shahzad M … Mushtaq MU. Impact of Obesity on Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy. 2025; 31(2): S309 (poster presented at the Transplantation and Cellular Therapy Meetings 2025, Honolulu, HI)

  13. Shahzad M … Mushtaq MU. Impact of Systemic Antibiotics Use on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy. 2025; 31(2): S510 (poster presented at the Transplantation and Cellular Therapy Meetings 2025, Honolulu, HI)

  14. Shahzad M … Mushtaq MU. Outcomes of Outpatient CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory B-Cell Lymphomas: A Systematic Review and Meta-Analysis. Transplantation and Cellular Therapy. 2025; 31(2): S397 (poster presented at the Transplantation and Cellular Therapy Meetings 2025, Honolulu, HI)

  15. Shahzad M … Mushtaq MU. Outcomes in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis. Transplantation and Cellular Therapy. 2025; 31(2): S398 (poster presented at the Transplantation and Cellular Therapy Meetings 2025, Honolulu, HI)

  16. Shahzad M … Mushtaq MU. Socioeconomic Disparities in Outcomes after Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy. 2025; 31(2): S310 (poster presented at the Transplantation and Cellular Therapy Meetings 2025, Honolulu, HI)

  17. Shahzad M … Mushtaq MU. Second Primary Malignancies after CAR T-Cell Therapy: A Systemic Review. Transplantation and Cellular Therapy. 2025; 31(2): S311 (poster presented at the Transplantation and Cellular Therapy Meetings 2025, Honolulu, HI)

  18. Shahzad M … Mushtaq MU. Allogeneic Hematopoietic Stem Cell Transplantation for Management of Histiocytic Sarcoma: A Systemic Review. Transplantation and Cellular Therapy. 2025; 31(2): S170 (poster presented at the Transplantation and Cellular Therapy Meetings 2025, Honolulu, HI)

  19. Iftikhar R, et al. Among other authors: Mushtaq MU. Real World Outcomes of Autologous Stem Cell Transplant in Multiple Myeloma: A Study on Behalf of Plasma Cell Dyscrasia Working Party of Pakistan Blood and Marrow Transplant Group. Transplantation and Cellular Therapy. 2025; 31(2): S326-327 (poster presented at the Transplantation and Cellular Therapy Meetings 2025, Honolulu, HI)

  20. Kamboj I, et al. Among other authors: Mushtaq MU. Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Report with the Cartitude-1 Trial. Transplantation and Cellular Therapy. 2025; 31(2): S222-223 (poster presented at the Transplantation and Cellular Therapy Meetings 2025, Honolulu, HI)

  21. Shoaib D, et al. Among other authors: Mushtaq MU. Avascular Necrosis (AVN) Outcomes in Allogeneic Stem Cell Transplant Recipients. Transplantation and Cellular Therapy. 2025; 31(2): S269-270 (poster presented at the Transplantation and Cellular Therapy Meetings 2025, Honolulu, HI)

  22. Rahman RL, et al. Among other authors: Mushtaq MU. Outcomes of Newly Diagnosed Myeloma Patients with Double-Hit and Single High-Risk Cytogenetics Receiving Autologous Stem Cell Transplant (ASCT). Transplantation and Cellular Therapy. 2025; 31(2): S417-418 (poster presented at the Transplantation and Cellular Therapy Meetings 2025, Honolulu, HI)

  23. Weise M, et al. Among other authors: Mushtaq MU. Social Determinants of Health (SDOH) and Access to CART for Multiple Myeloma. Transplantation and Cellular Therapy. 2025; 31(2): S361-362 (poster presented at the Transplantation and Cellular Therapy Meetings 2025, Honolulu, HI)

  24. Laharwal, et al. Among other authors: Mushtaq MU. Use of Doublet Maintenance (Bortezomib-Lenalidomide) Vs Monotherapy Lenalidomide As Maintenance Therapy Post-Transplant of Patients with High-Risk Cytogenetics Myeloma. Transplantation and Cellular Therapy. 2025; 31(2): S426 (poster presented at the Transplantation and Cellular Therapy Meetings 2025, Honolulu, HI)

  25. Mushtaq MU, et al. Outcomes of Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis in Elderly Patients over 70 Years of Age with Acute Leukemia and Myelodysplastic Syndromes. Blood. 2024; 144(S1): 7379 (poster presented at the American Society of Hematology Annual Meeting 2024, San Diego, CA)

  26. Mushtaq MU, et al. Outcomes after Bone Marrow Versus Peripheral Blood Matched Unrelated Donor Hematopoietic Stem Cell Transplantation for Acute Leukemia. Blood. 2024; 144(S1): 7283

  27. Mushtaq MU, et al. Impact of Graft Cell Dose on Outcomes after Matched Sibling Donor Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis. Blood. 2024; 144(S1): 7379

  28. Venkatesh P, et al. Among other authors: Mushtaq MU. Characterizing Treatment Patterns in Multiple Myeloma Patients with High-Risk Cytogenetics: A 15-Year-Study. Blood. 2024; 144(S1): 6943

  29. Shahzad M, et al. Among other authors: Mushtaq MU. Trends and Disparities in Idiopathic Thrombocytopenic Purpura-Related Mortality in the United States: A Retrospective Study over Two Decades. Blood. 2024; 144(S1): 3947 (poster presented at the American Society of Hematology Annual Meeting 2024, San Diego, CA)

  30. Mushtaq MU, et al. Outcomes after Bone Marrow Versus Peripheral Blood Haploidentical Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide-Based GVHD Prophylaxis. Blood. 2024; 144(S1): 4877 (poster presented at the American Society of Hematology Annual Meeting 2024, San Diego, CA)

  31. Weise M, et al. Among other authors: Mushtaq MU. Stalled CARS: Examining the Real-World Impact of Waiting for CART in Patients with Multiple Myeloma. Blood. 2024; 144(S1): 6937

  32. Shahzad M … Mushtaq MU. Allogeneic Hematopoietic Stem Cell Transplantation for Management of Histiocytic Sarcoma: A Systemic Review. Blood. 2024; 144(S1): 7394

  33. Chaudhary SG … Mushtaq MU. Impact of CD34+ Graft Cell Dose on Outcomes after Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis. Blood. 2024; 144(S1): 7424

  34. Rahman RL, et al. Among other authors: Mushtaq MU. Outcomes of Double-Hit and Single High Risk Cytogenetic Newly Diagnosed Myeloma in Transplant Eligible Patients. Blood. 2024; 144(S1): 6953

  35. Shaikh H, et al. Among other authors: Mushtaq MU. Real-World Safety and Efficacy of Talquetamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma. Blood. 2024; 144(S1): 7860 (poster presented at the American Society of Hematology Annual Meeting 2024, San Diego, CA)

  36. Iqbal Q, et al. Among other authors: Mushtaq MU. Outcomes of Hematopoietic Stem Cell Transplantation in Primary Plasma Cell Leukemia: A Systematic Review and Meta-Analysis. Blood. 2024; 144(S1): 3555 (poster presented at the American Society of Hematology Annual Meeting 2024, San Diego, CA)

  37. Shahzad M … Mushtaq MU. Impact of Minimal Residual Disease Status on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia. Blood. 2024; 144(S1): 3552 (poster presented at the American Society of Hematology Annual Meeting 2024, San Diego, CA)

  38. Shoaib D, et al. Among other authors: Mushtaq MU. Avascular Necrosis (AVN) Outcomes in Allogeneic Stem Cell Transplant Recipients. Blood. 2024; 144(S1): 7414

  39. Shahzad M … Mushtaq MU. Impact of Graft Cell Dose on Outcomes after Matched Sibling Donor Bone Marrow Transplantation with Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis. Blood. 2024; 144(S1): 7277

  40. Snyder J, et al. Among other authors: Mushtaq MU. Impact of Absolute Lymphocyte Count on Efficacy and Toxicity of T-Cell Engagers in Non-Hodgkin’s Lymphoma. Blood. 2024; 144(S1): 7731

  41. Ayoobkhan FS, et al. Among other authors: Mushtaq MU. Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS) for Chimeric Antigen Receptor T-Cell Therapy (CAR-T) and T-Cell Engager Antibody (TCE) in Myeloma and Lymphoma. Blood. 2024; 144(S1): 5163 (poster presented at the American Society of Hematology Annual Meeting 2024, San Diego, CA)

  42. Shahzad M … Mushtaq MU. Correlates of Patient-Reported Outcomes Following Allogeneic Unrelated Donor Hematopoietic Stem Cell Transplantation. Blood. 2024; 144(S1): 4936 (poster presented at the American Society of Hematology Annual Meeting 2024, San Diego, CA)

  43. Venkatesh P, et al. Among other authors: Mushtaq MU. Optimal Treatment for Newly Diagnosed Primary Plasma Cell Leukemia: A Retrospective Multicenter Analysis. Blood. 2024; 144(S1): 3317 (poster presented at the American Society of Hematology Annual Meeting 2024, San Diego, CA)

  44. Katz H, et al. Among other authors: Mushtaq MU. The Use of the Montreal Cognitive Assessment to Predict Neurotoxicity Post CD19 and BCMA CART. Blood. 2024; 144(S1): 5030 (poster presented at the American Society of Hematology Annual Meeting 2024, San Diego, CA)

  45. Shahzad M … Mushtaq MU. Incidence, Patterns, and Outcomes of Fungal Infections in Patients with Graft Versus Host Disease Requiring Systemic Steroids Following Allogeneic Hematopoietic Cell Transplantation. Blood. 2024; 144(S1): 5372

  46. Shahzad M … Mushtaq MU. Efficacy of Ruxolitinib in Patients with Hemophagocytic Lymphohistiocytosis: A Systematic Review. Blood. 2024; 144(S1): 5372

  47. Amin MK, et al. Among other authors: Mushtaq MU. Trends and Disparities in Sickle Cell Disease-Related Mortality in the United States from 1999 to 2020: Insights from the CDC Wonder Database. Blood. 2024; 144(S1): 1130 (poster presented at the American Society of Hematology Annual Meeting 2024, San Diego, CA)

  48. Shahzad M … Mushtaq MU. Outcomes with Venetoclax and Hypomethylating Agents in Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis. Blood. 2024; 144(S1): 4932 (poster presented at the American Society of Hematology Annual Meeting 2024, San Diego, CA)

  49. Shahzad M … Mushtaq MU. Outcomes of Melphalan Versus Busulfan with Fludarabine Reduced Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. Blood. 2024; 144(S1): 7426

  50. Amin MK, et al. Among other authors: Mushtaq MU. Efficacy of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in High Risk Relapsed Multiple Myeloma: Multicenter Real-World Experience. Blood. 2024; 144(S1): 7034

  51. Amin MK, et al. Among other authors: Mushtaq MU. Impact of Minimal Residual Disease Status on Multiple Myeloma Outcomes: A Systematic Review. Blood. 2024; 144(S1): 6952

  52. Shaikh H, et al. Among other authors: Mushtaq MU. Talquetamab in B Cell Maturation Antigen (BCMA) Exposed Relapsed-Refractory Multiple Myeloma Patients. Blood. 2024; 144(S1): 5170.4 (poster presented at the American Society of Hematology Annual Meeting 2024, San Diego, CA)

  53. Shahzad M … Mushtaq MU. Impact of Conditioning Intensity on Allogeneic Hematopoietic Stem Cell Transplant Outcomes in Patients with Acute Leukemia and Myelodysplastic Syndromes. Blood. 2024; 144(S1): 4860 (poster presented at the American Society of Hematology Annual Meeting 2024, San Diego, CA)

  54. Mushtaq MU, et al. Factors Associated with Graft-Versus-Host Disease after Related Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis. Blood. 2024; 144(S1): 3517 (poster presented at the American Society of Hematology Annual Meeting 2024, San Diego, CA)

  55. Ayoobkhan FS … Mushtaq MU. Oncologists’ Perspectives and Practices on Minimal Residual Disease Testing in Multiple Myeloma. Blood. 2024; 144(S1): 5045 (poster presented at the American Society of Hematology Annual Meeting 2024, San Diego, CA)

  56. Alsaddi Z, et al. Among other authors: Mushtaq MU. Comparison of Standard of Care with or without a PD-1/Pdl-1 Inhibitor for the Treatment of Multiple Myeloma: A Meta-Analysis of Phase II and III Randomized Controlled Trials. Blood. 2024; 144(S1): 7009

  57. Shahzad M … Mushtaq MU. Socioeconomic Disparities in Allogeneic Hematopoietic Cell Transplant Outcomes. Blood. 2024; 144(S1): 3556 (poster presented at the American Society of Hematology Annual Meeting 2024, San Diego, CA)

  58. Chaudhary SG … Mushtaq MU. Impact of CD34+ Graft Cell Dose on Outcomes after Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis. Blood. 2024; 144(S1): 3503 (poster presented at the American Society of Hematology Annual Meeting 2024, San Diego, CA)

  59. Shahzad M … Mushtaq MU. “Unveiling the Competition” Comprehensive Analysis of Hematology and Oncology Fellowship Trends through NRMP Data (2011-2024) in United States (US). Blood. 2024; 144(S1): 7947

  60. Shahzad M … Mushtaq MU. Incidence and Severity of Cytopenias Secondary to CD19-Targeted CAR-T Cell Therapy: A Systemic Review and Meta-Analysis. Blood. 2024; 144(S1): 7242

  61. Mushtaq MU, et al. Impact of Graft Cell Dose on Outcomes after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis. Blood. 2024; 144(S1): 7278

  62. Casteen EJ, et al. Among other authors: Mushtaq MU. Exploring the Global Landscape of Open Access Publication Models and Their Correlation with the Impact Factor in the Field of Hematology/Oncology. Blood. 2024; 144(S1): 7950

  63. McGuirk M … Mushtaq MU. Sociodemographic Determinants of Allogeneic Hematopoietic Stem Cell Transplant Outcomes. Blood. 2024; 144(S1): 7410

  64. Shahzad M, et al. Among other authors: Mushtaq MU. Trends and Disparities in Autoimmune Hemolytic Anemia-Related Mortality in the United States from 1999 to 2020: Insights from the CDC Wonder Database. Blood. 2024; 144(S1): 5232

  65. Laharwal MM, et al. Among other authors: Mushtaq MU. Use of Doublet Maintenance (Bortezomib-Lenalidomide) Vs Monotherapy Lenalidomide As Maintenance Therapy Post-Transplant of Patients with High-Risk Cytogenetics Myeloma. Blood. 2024; 144(S1): 7107

  66. McGuirk M … Mushtaq MU. Correlates of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation. Blood. 2024; 144(S1): 7408

  67. Iftikhar R, et al. Among other authors: Mushtaq MU. Real World Outcomes of Autologous Stem Cell Transplant in Multiple Myeloma: A Study on Behalf of Plasma Cell Dyscrasia Working Party of Pakistan Blood and Marrow Transplant Group. Blood. 2024; 144(S1): 7838

  68. Shahzad M … Mushtaq MU. Outcomes of Outpatient CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory B-Cell Lymphomas: A Systematic Review and Meta-Analysis. Blood. 2024; 144(S1): 6502

  69. Shahzad M … Mushtaq MU. Busulfan with Cyclophosphamide Versus Busulfan with Fludarabine for Myeloablative Conditioning in Acute Myeloid Leukemia and Myelodysplastic Syndrome in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplant- a Systematic Review and Meta-Analysis. Blood. 2024; 144(S1): 7284

  70. McGuirk M … Mushtaq MU. Correlates of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation. Blood. 2024; 144(S1): 7305

  71. Chaudhary SG … Mushtaq MU. Impact of CD34+ Graft Cell Dose on Outcomes after Allogeneic Peripheral Blood Stem Cell Transplantation. Blood. 2024; 144(S1): 7305

  72. Sayed NB, et al. Among other authors: Mushtaq MU. A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment. Blood. 2024; 144(S1): 7023

  73. Snyder J, et al. Among other authors: Mushtaq MU. A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment. Blood. 2024; 144(S1): 7098

  74. Chaudhary SG … Mushtaq MU. Sociodemographic and Patient-Related Determinants of Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis. Blood. 2024; 144(S1): 3524 (poster presented at the American Society of Hematology Annual Meeting 2024, San Diego, CA)

  75. Shahzad M … Mushtaq MU. Efficacy of Axatilimab in the Management of Chronic Graft-Versus-Host Disease. Blood. 2024; 144(S1): 7361

  76. Shahzad M … Mushtaq MU. Impact of Systemic Antibiotics Use on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation. Blood. 2024; 144(S1): 7409.

  77. Mushtaq MU, et al. Sociodemographic and Patient-Related Determinants of Outcomes after Allogeneic Hematopoietic Cell Transplantation in Acute Leukemia and Myelodysplastic Syndromes. Blood. 2024; 144(S1): 7902

  78. Shahzad M … Mushtaq MU. Impact of Obesity on Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation. Blood. 2024; 144(S1): 7421

  79. Shahzad M, et al. Among other authors: Mushtaq MU. Trends and Disparities in Acute Lymphoblastic Leukemia-Related Mortality in the United States from 1999 to 2020: Insights from the CDC Wonder Database. Blood. 2024; 144(S1): 5103 (poster presented at the American Society of Hematology Annual Meeting 2024, San Diego, CA)

  80. Habib A, et al. Among other authors: Mushtaq MU. A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment. Blood. 2024; 144(S1): 7037

  81. Weise M, et al. Among other authors: Mushtaq MU. Social Determinants of Health (SDOH) and Access to CART for Multiple Myeloma. Blood. 2024; 144(S1): 5162 (poster presented at the American Society of Hematology Annual Meeting 2024, San Diego, CA)

  82. Shahzad M … Mushtaq MU. Second Primary Malignancies after CAR T-Cell Therapy: A Systemic Review. Blood. 2024; 144(S1): 7237.

  83. Shahzad M … Mushtaq MU. Outcomes after Bone Marrow Versus Peripheral Blood Stem Cells Haploidentical Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis. Blood. 2024; 144(S1): 7425.

  84. Zayad A, et al. Among other authors: Mushtaq MU. The Scope of Academic and Industry Sponsorship in Shaping the Future of AL Amyloidosis Research. Blood. 2024; 144(S1): 7595

  85. Shahzad M … Mushtaq MU. Pattern, Incidence, and Outcomes of Invasive Fungal Infections after Allogeneic Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis. Blood. 2024; 144(S1): 3505 (poster presented at the American Society of Hematology Annual Meeting 2024, San Diego, CA)

  86. Shahzad M … Mushtaq MU. Outcomes in Underweight Allogeneic Hematopoietic Stem Cell Transplantation Recipients. Blood. 2024; 144(S1): 7377.

  87. Shahzad M … Mushtaq MU. Outcomes of Autologous Hematopoietic Stem Cell Transplantation in Patients with Light-Chain Amyloidosis: A Systematic Review and Meta-Analysis. Blood. 2024; 144(S1): 4670 (poster presented at the American Society of Hematology Annual Meeting 2024, San Diego, CA)

  88. Chang D, et al. Among other authors: Mushtaq MU. A Real-World Analysis of the Safety and Efficacy of BCMA-Directed CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment. Blood. 2024; 144(S1): 2404 (poster presented at the American Society of Hematology Annual Meeting 2024, San Diego, CA)

  89. Habib A, et al. Among other authors: Mushtaq MU. A Real-World Analysis of the Safety and Efficacy of BCMA-Directed CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment. Blood. 2024; 144(S1): 2009 (poster presented at the American Society of Hematology Annual Meeting 2024, San Diego, CA)

  90. Snyder J, et al. Among other authors: Mushtaq MU. Evaluation of Teclistamab in BCMA-Directed Therapy Exposed Versus Naïve in Relapsed/Refractory Multiple Myeloma. Blood. 2024; 144(S1): 2411.7 (poster presented at the American Society of Hematology Annual Meeting 2024, San Diego, CA)

  91. Kamboj I, et al. Among other authors: Mushtaq MU. Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial. Blood. 2024; 144(S1): 2411.2 (poster presented at the American Society of Hematology Annual Meeting 2024, San Diego, CA)

  92. Mansour R, et al. Among other authors: Mushtaq MU. Comparative Efficacy of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Aged 70 and Above: A Multicenter Study. Blood. 2024; 144(S1): 1965 (poster presented at the American Society of Hematology Annual Meeting 2024, San Diego, CA)

  93. Zayad A, et al. Among other authors: Mushtaq MU. The Impact of Financial Support on the Development of Clinical Research in Multiple Myeloma: An in-Depth Analysis (1980-2024). Blood. 2024; 144(S1): 2288 (poster presented at the American Society of Hematology Annual Meeting 2024, San Diego, CA)

  94. Mushtaq MU, et al. Impact of Conditioning Intensity on Outcomes after Allogeneic Related Donor HCT with Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis in Acute Leukemia and Myelodysplastic Syndromes. Blood. 2024; 144(S1): 2141 (poster presented at the American Society of Hematology Annual Meeting 2024, San Diego, CA)

  95. Scott LN, et al. Among other authors: Mushtaq MU. Utilization of Investigations for Neurotoxicity in CD19 and BCMA CAR-T Recipients. Blood. 2024; 144(S1): 389 (oral presentation at the American Society of Hematology Annual Meeting 2024, San Diego, CA)

  96. Shahzad M … Mushtaq MU. Outcomes after Bone Marrow Versus Peripheral Blood Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide-Based Graft Versus Host Disease Prophylaxis. Blood. 2024; 144(S1): 2118 (poster presented at the American Society of Hematology Annual Meeting 2024, San Diego, CA)

  97. Shahzad M … Mushtaq MU. Factors Associated with Acute and Chronic Graft-Versus-Host Disease after Matched Unrelated Donor Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide-Based GVHD Prophylaxis. Blood. 2024; 144(S1): 2147 (poster presented at the American Society of Hematology Annual Meeting 2024, San Diego, CA)

  98. Mushtaq MU, et al. Outcomes after Bone Marrow Versus Peripheral Blood Matched Sibling Donor Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide-Based GVHD prophylaxis. Blood. 2024; 144(S1): 2119 (poster presented at the American Society of Hematology Annual Meeting 2024, San Diego, CA)

  99. Chaudhary SG … Mushtaq MU. Sociodemographic and Patient-Related Determinants of Outcomes after Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis. Blood. 2024; 144(S1): 2122 (poster presented at the American Society of Hematology Annual Meeting 2024, San Diego, CA)

  100. Shahzad M … Mushtaq MU. Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients Aged over 70 Years with Myelofibrosis. Blood. 2024; 144(S1): 2172 (poster presented at the American Society of Hematology Annual Meeting 2024, San Diego, CA)

  101. Mushtaq MU, et al. Outcomes after Matched Sibling Donor Versus Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis. Blood. 2024; 144(S1): 2102 (poster presented at the American Society of Hematology Annual Meeting 2024, San Diego, CA)

  102. Amin MK, et al. Among other authors: Mushtaq MU. Trends and Disparities in Sickle Cell Disease-Related Mortality in the United States from 1999 to 2020: Insights from the CDC Wonder Database. Blood. 2024; 144(S1): 1130 (poster presented at the American Society of Hematology Annual Meeting 2024, San Diego, CA)

  103. Zulfiqar F … Mushtaq MU. Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Outcomes In Rheumatological Autoimmune Disorders: A Systematic Review. Clinical Lymphoma, Myeloma & Leukemia. 2024 (poster presented at the Society of Hematology & Oncology Meeting 2024, Houston, TX)

  104. Shahzad M … Mushtaq MU. Efficacy of Axatilimab in the Management of Refractory Chronic Graft-Versus-Host Disease. Clinical Lymphoma, Myeloma & Leukemia. 2024 (poster presented at the Society of Hematology & Oncology Meeting 2024, Houston, TX)

  105. Khan MA … Mushtaq MU. Efficacy of Ruxolitinib With Corticosteroids in Idiopathic Pneumonia Syndrome Post-Allogeneic Hematopoietic Stem Cell Transplantation: A Single- Center Experience and Systematic Review. Clinical Lymphoma, Myeloma & Leukemia. 2024 (poster presented at the Society of Hematology & Oncology Meeting 2024, Houston, TX)

  106. Shafique N … Mushtaq MU. Hemophagocytic Lymphohistiocytosis Co-Presenting With Non-Cirrhotic Portal Hypertensive Gastropathy: A Case Report. Clinical Lymphoma, Myeloma & Leukemia. 2024 (poster presented at the Society of Hematology & Oncology Meeting 2024, Houston, TX)

  107. Shahzad M, et al. Among other authors: Mushtaq MU. Outcomes With Epcoritamab in Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis. Clinical Lymphoma, Myeloma & Leukemia. 2024 (poster presented at the Society of Hematology & Oncology Meeting 2024, Houston, TX)

  108. Shahzad M, et al. Among other authors: Mushtaq MU. Advancing Multiple Myeloma Treatment: A Systematic Review and Meta-Analysis of Cereblon E3 Ligase Modulatory Drugs (CELMoDs) Impact on Patient Outcomes. Clinical Lymphoma, Myeloma & Leukemia. 2024 (poster presented at the Society of Hematology & Oncology Meeting 2024, Houston, TX)

  109. Shah MDA, et al. Among other authors: Mushtaq MU. Disparities in Myelodysplastic Syndromes Mortality Among Older Adults in the United States: A CDC WONDER Database Analysis. Clinical Lymphoma, Myeloma & Leukemia. 2024 (poster presented at the Society of Hematology & Oncology Meeting 2024, Houston, TX)

  110. Shah MDA, et al. Among other authors: Mushtaq MU. Disparities in Acute Leukemia-Related Mortality Among Reproductive-Aged Women in the United States: A CDC WONDER Database Analysis. Clinical Lymphoma, Myeloma & Leukemia. 2024 (poster presented at the Society of Hematology & Oncology Meeting 2024, Houston, TX)

  111. Wesson W, et al. Among other authors: Mushtaq MU. Neurocognitive Testing to Predict ICANS Post-Chimeric Antigen (CAR) T-Cell Therapy. Clinical Lymphoma, Myeloma & Leukemia. 2024 (poster presented at the Society of Hematology & Oncology Meeting 2024, Houston, TX)

  112. Ayoobkhan FS, et al. Among other authors: Mushtaq MU. Unveiling the Future: Insights From the Current Landscape in Solid Tumor CAR T Clinical Trials. Clinical Lymphoma, Myeloma & Leukemia. 2024 (poster presented at the Society of Hematology & Oncology Meeting 2024, Houston, TX)

  113. Zulfiqar F … Mushtaq MU. Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Outcomes In Rheumatological Autoimmune Disorders: A Systematic Review. Clinical Lymphoma, Myeloma & Leukemia. 2024 (poster presented at the Society of Hematology & Oncology Meeting 2024, Houston, TX)

  114. Vyas A… Mushtaq MU. Racial disparities in the intervention trials in colon cancer. Journal of Clinical Oncology. 2024; 42(16S): e13718

  115. Wesson W, et al. Among other authors: Mushtaq MU. Characterizing clinical trials for CAR T targeting solid tumors from 2018 to 2023: A systematic review. Journal of Clinical Oncology. 2024; 42(16S): e15080

  116. Wesson W, et al. Among other authors: Mushtaq MU. Neurocognitive testing to predict ICANS post-CAR T. Journal of Clinical Oncology. 2024; 42(16S): e19003

  117. Shahzad M … Mushtaq MU. Comparison of Biosimilar Filgrastim (Nivestym) Versus Originator Filgrastim (Neupogen) for Peripheral Blood Stem Cell Mobilization for Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy. 2024; 30: S172. (poster presented at the Transplantation and Cellular Therapy Meetings 2024, San Antonio, TX)

  118. Amin MK … Mushtaq MU. Outcomes after Bone Marrow Versus Peripheral Blood Haploidentical Hematopoietic Stem Cell Transplantation Using Posttransplant Cyclophosphamide-Based GVHD Prophylaxis. Transplantation and Cellular Therapy. 2024; 30: S241-42. (poster presented at the Transplantation and Cellular Therapy Meetings 2024, San Antonio, TX)

  119. Wesson W, et al. Among other authors: Mushtaq MU. A Multicenter Experience: Duration of Mandatory CRS and Icans Monitoring for Myeloma and Lymphoma CAR-T Recipients. Transplantation and Cellular Therapy. 2024; 30: S207-S208. (poster presented at the Transplantation and Cellular Therapy Meetings 2024, San Antonio, TX)

  120. Venkatesh P, et al. Among other authors: Mushtaq MU. VD-PACE As Salvage and Bridging Therapy to Transplant and Cellular Therapy in Triple Class Relapsed/Refractory Multiple Myeloma. Transplantation and Cellular Therapy. 2024; 30: S389-S390. (poster presented at the Transplantation and Cellular Therapy Meetings 2024, San Antonio, TX)

  121. Tabak C, et al. Among other authors: Mushtaq MU. Chimeric Antigen Receptor T-Cell (CAR-T) Access Among Rural and Health Professional Shortage Area (HPSA) Populations in the Midwest. Transplantation and Cellular Therapy. 2024; 30: S323. (poster presented at the Transplantation and Cellular Therapy Meetings 2024, San Antonio, TX)

  122. Soomro MA, et al. Among other authors: Mushtaq MU. Outcomes in Multiple Myeloma Patients Progressing after BCMA-Directed Chimeric Antigen Receptor T Cell (CART) Therapy. Transplantation and Cellular Therapy. 2024; 30: S373. (poster presented at the Transplantation and Cellular Therapy Meetings 2024, San Antonio, TX)

  123. Rashid A, et al. Among other authors: Mushtaq MU. BCMA Re-Emergence: Can It Serve As a Prognostic Biomarker in Multiple Myeloma after CAR-T? Transplantation and Cellular Therapy. 2024; 30: S194-S195. (poster presented at the Transplantation and Cellular Therapy Meetings 2024, San Antonio, TX)

  124. Lutfi F, et al. Among other authors: Mushtaq MU. Permissive Cardiotoxicity As a Guiding Principle to CAR-T Therapy with Reduced Ejection Fraction Heart Failure. Transplantation and Cellular Therapy. 2024; 30: S229. (poster presented at the Transplantation and Cellular Therapy Meetings 2024, San Antonio, TX)

  125. Khaliq A, et al. Among other authors: Mushtaq MU. The Glass Wall: Gendered Authorship Disparities in in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma. Transplantation and Cellular Therapy. 2024; 30: S208. (poster presented at the Transplantation and Cellular Therapy Meetings 2024, San Antonio, TX)

  126. Atallah R, et al. Among other authors: Mushtaq MU. The GLAMM1 Study – Global Access to Myeloma Medications: Potential Barriers to Chimeric Antigen Receptors (CART) and T-Cell-Engaging Bispecific Antibodies (TCE) Globally. Transplantation and Cellular Therapy. 2024; 30: S373-S374. (poster presented at the Transplantation and Cellular Therapy Meetings 2024, San Antonio, TX)

  127. Atallah R, et al. Among other authors: Mushtaq MU. The TACTUM23 Study: Access to Cellular Therapies in Multiple Myeloma: Perspectives of Treating Versus Referring Physicians in 2023. Transplantation and Cellular Therapy. 2024; 30: S375-S376. (poster presented at the Transplantation and Cellular Therapy Meetings 2024, San Antonio, TX)

  128. Shahzad M … Mushtaq MU. Comparison of Biosimilar Filgrastim (Nivestym) Versus Originator Filgrastim (Neupogen) for Peripheral Blood Stem Cell Mobilization for Allogeneic Hematopoietic Stem Cell Transplantation Blood. 2023; 142 (S1): 3523. (poster presented at the American Society of Hematology Annual Meeting 2023, San Diego, CA)

  129. Amin M … Mushtaq MU. Outcomes after Bone Marrow Versus Peripheral Blood Haploidentical Hematopoietic Stem Cell Transplantation Using Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis. Blood. 2023; 142 (S1): 2242. (poster presented at the American Society of Hematology Annual Meeting 2023, San Diego, CA)

  130. Khaliq A, et al. Among other authors: Mushtaq MU. The Glass Wall: Gendered Authorship Disparities in in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma. Blood. 2023; 142 (S1): 2344. (poster presented at the American Society of Hematology Annual Meeting 2023, San Diego, CA)

  131. Mammadzadeh A, et al. Among other authors: Mushtaq MU. Global Access to Multiple Myeloma Medications (GLAMM-2 Study): Access and Barriers to Chemoimmunotherapies and Transplant. Blood. 2023; 142 (S1): 4727. (poster presented at the American Society of Hematology Annual Meeting 2023, San Diego, CA)

  132. Snyder J, et al. Among other authors: Mushtaq MU. Efficacy of Daratumumab-Based Regimens in Anti-CD38 Treatment-Naïve Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics. Blood. 2023; 142 (S1): 1985. (poster presented at the American Society of Hematology Annual Meeting 2023, San Diego, CA)

  133. Atallah R, et al. Among other authors: Mushtaq MU. The GLAMM1 Study – Global Access to Myeloma Medications: Potential Barriers to Chimeric Antigen Receptors (CART) and T-Cell-Engaging Bispecific Antibodies (TCE) Globally. Blood. 2023; 142 (S1): 3327. (poster presented at the American Society of Hematology Annual Meeting 2023, San Diego, CA)

  134. Al-Ramahi J … Mushtaq MU. Outcomes after Bone Marrow Versus Peripheral Blood Stem Cell Matched Unrelated Donor Hematopoietic Stem Cell Transplantation. Blood. 2023; 142 (S1): 7028.

  135. Soomro MA, et al. Among other authors: Mushtaq MU. Outcomes Multiple Myeloma Patients Progressing after BCMA-Directed Chimeric Antigen Receptor T Cell (CART) Therapy. Blood. 2023; 142 (S1): 6900.

  136. Lutfi F, et al. Among other authors: Mushtaq MU. Permissive Cardiotoxicity As a Guiding Principle to CAR-T Therapy with Reduced Ejection Fraction Heart Failure. Blood. 2023; 142 (S1): 6916.

  137. Venkatesh P, et al. Among other authors: Mushtaq MU. Vdpace As Salvage Therapy in Triple Class Relapse/Refractory Multiple Myeloma. Blood. 2023; 142 (S1): 6694.

  138. Atallah R, et al. Among other authors: Mushtaq MU. Trends in Access to Cellular Therapies in Multiple Myeloma (TACTUM): Perspectives of Treating Versus Referring Physicians. Blood. 2023; 142 (S1): 6678.

  139. Wesson W, et al. Among other authors: Mushtaq MU. Balancing Monitoring and Access: Optimal Duration of Monitoring for CD19 and BCMA CART Recipients for Lymphoma and Myeloma. Blood. 2023; 142 (S1): 6914.

  140. Rashid A, et al. Among other authors: Mushtaq MU. BCMA Re-Emergence As a Prognostic Indicator of Clinical Relapse after Chimeric Antigen Receptor T-Cell Therapy (CART) in Multiple Myeloma. Blood. 2023; 142 (S1): 6801.

  141. Rashid A, et al. Among other authors: Mushtaq MU. Trends of BCMA Re-emergence Post Ide-cel and Cilta-cel in Myeloma. Clinical Lymphoma, Myeloma & Leukemia. 2023 (poster presented at the Society of Hematology & Oncology Meeting 2023, Houston, TX)

  142. Ahmed N, et al. Among other authors: Mushtaq MU. Rural communities and health professional shortage areas (HPSA) and access to immune effector cellular therapy and lymphoma/myeloma clinical trials. Journal of Clinical Oncology. 2023; 41(16S): e18633

  143. Venkatesh P, et al. Among other authors: Mushtaq MU. Efficacy of teclistamab in patients (pts) with heavily pretreated, relapsed/refractory multiple myeloma (RRMM), including those refractory to penta RRMM and BCMA (B-cell maturation antigen) directed therapy (BDT). Journal of Clinical Oncology. 2023; 41(16S): e20044

  144. McGuirk M … Mushtaq MU. Cytomegalovirus reactivation after matched unrelated donor and haploidentical hematopoietic cell transplantation. Bone Marrow Transplantation. 2023. (oral presentation at the European Society for Blood and Marrow Transplantation Annual Meeting 2023, Paris, France)

  145. Nelson M … Mushtaq MU. Concurrent Intravenous Immunoglobulin and Platelet Transfusion for Refractory Alloimmune Thrombocytopenia in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy. 2023; 29(2): S148-49. (poster presented at the Transplantation and Cellular Therapy Meetings 2023, Orlando, FL)

  146. Hussain A … Mushtaq MU. Outcomes with Allogeneic Hematopoietic Stem Cell Transplantation in NPM1-Mutated Acute Myeloid Leukemia: A Systematic Review And Meta-Analysis. Transplantation and Cellular Therapy. 2023; 29(2): S125-26. (poster presented at the Transplantation and Cellular Therapy Meetings 2023, Orlando, FL)

  147. Amad Ud Din M … Mushtaq MU. The Impact of Nosocomial Influenza Infection on Hospitalization Outcomes in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplant: A National Inpatient Database Analysis (2002-19). Transplantation and Cellular Therapy. 2023; 29(2): S328-29. (poster presented at the Transplantation and Cellular Therapy Meetings 2023, Orlando, FL)

  148. Wesson W, Nelson M, Mushtaq MU, et al. Risk Factors and Outcomes for Patients with Persistent Cytopenia Following Administration of CD19 CAR-T Cell Therapy in B Cell Lymphoma. Transplantation and Cellular Therapy. 2023; 29(2): S187-88. (poster presented at the Transplantation and Cellular Therapy Meetings 2023, Orlando, FL)

  149. Wesson W, Nelson M, Mushtaq MU, et al. Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel (tisa-cel) Recipients for B Cell Malignancies. Transplantation and Cellular Therapy. 2023; 29(2): S221-22. (poster presented at the Transplantation and Cellular Therapy Meetings 2023, Orlando, FL)

  150. Leal J, et al. Among other authors: Mushtaq MU. Implementing a Diabetes Telehealth Pilot Clinic for the Management of Steroid-Induced Hyperglycemia in Patients with Graft Versus Host Disease. Transplantation and Cellular Therapy. 2023; 29(2): S578. (poster presented at the Transplantation and Cellular Therapy Meetings 2023, Orlando, FL)

  151. Mushtaq MU, et al. Outcomes with HLA-Matched Unrelated Donor Versus Haploidentical Hematopoietic Cell Transplantation: A Single-Center Experience. Transplantation and Cellular Therapy. 2023; 29(2): S231-32. (poster presented at the Transplantation and Cellular Therapy Meetings 2023, Orlando, FL)

  152. Mushtaq MU, et al. Outcomes with CD34-Selected Stem Cell Boost for Poor Graft Function and Graft Failure after Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy. 2023; 29(2): S178-79. (poster presented at the Transplantation and Cellular Therapy Meetings 2023, Orlando, FL)

  153. Mushtaq MU, et al. Lessons Learned from COVID-19 Pandemic: Outcomes after Sars-Cov-2 Infection in Hematopoietic Cell Transplant and Cell Therapy Recipients. Transplantation and Cellular Therapy. 2023; 29(2): S326-27. (poster presented at the Transplantation and Cellular Therapy Meetings 2023, Orlando, FL)

  154. Shahzad M … Mushtaq MU. Outcomes after HLA-Mismatched Unrelated Donor Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide for Graft-Vs-Host Disease Prophylaxis: A Systematic Review and Meta-Analysis. Transplantation and Cellular Therapy. 2023; 29(2): S272. (poster presented at the Transplantation and Cellular Therapy Meetings 2023, Orlando, FL)
Media Presentations and Interviews:
  1. Are Stem Cell Transplants Safe for Myelofibrosis Patients Over 70? | ASH24. HealthTree Foundation for Blood Cancers. December 2024.

  2. ASH 2024 | Outcomes of matched sibling versus haploidentical alloSCT with PTCy-based GvHD prophylaxis. The Video Journal of Hematology and Hematological Oncology. December 2024.

  3. ASH 2024 | Outcomes of alloSCT with PTCy-based GvHD prophylaxis in elderly patients with acute leukemia or MDS. The Video Journal of Hematology and Hematological Oncology. December 2024.

  4. ASH 2024 | Outcomes of alloSCT in older patients aged over 70 years with myelofibrosis. The Video Journal of Hematology and Hematological Oncology. December 2024.

  5. Exploring the Future of Cancer Care: What is Tumor-Infiltrating Lymphocyte (TIL) Therapy? University of Kansas Cancer Center Bench to Bedside Podcast. May 2024.

Updated March 20, 2025

    1. Are Stem Cell Transplants Safe for Myelofibrosis Patients Over 70? | ASH24. HealthTree Foundation for Blood Cancers. December 2024.
      https://www.youtube.com/watch?v=qGWGhOMQ0lA

    2. ASH 2024 | Outcomes of matched sibling versus haploidentical alloSCT with PTCy-based GvHD prophylaxis. The Video Journal of Hematology and Hematological Oncology. December 2024.
      https://www.youtube.com/watch?v=I1o1YOP7qWQ

    3. ASH 2024 | Outcomes of alloSCT with PTCy-based GvHD prophylaxis in elderly patients with acute leukemia or MDS. The Video Journal of Hematology and Hematological Oncology. December 2024.
      https://www.youtube.com/watch?v=gAC5c3mSyg8

    4. ASH 2024 | Outcomes of alloSCT in older patients aged over 70 years with myelofibrosis. The Video Journal of Hematology and Hematological Oncology. December 2024.
      https://www.youtube.com/watch?v=KMAIr8KLrOQ

    5. Exploring the Future of Cancer Care: What is Tumor-Infiltrating Lymphocyte (TIL) Therapy? University of Kansas Cancer Center Bench to Bedside Podcast. May 2024.
      https://podcasts.apple.com/us/podcast/exploring-the-future-of-cancer-care-what-is/id1583289928?i=1000656396195

      https://open.spotify.com/episode/0n9V63mQg8VoFCtVs5iJze